BioPharma

The agreements will bolster India's arsenal of drugs to battle its catastrophic second wave of the pandemic, which has led to an acute shortage of coronavirus medicines including remdesivir and tocilizumab.

Despite the industry’s lobbying efforts, the Biden administration bowed to intense pressure at home and abroad and announced support for temporarily waiving international patent protections for COVID vaccines and manufacturing technology. 

A federal judge warns drug manufacturers they won't be able to plea out of an 800% price hike on diabetes med. Mike Papantonio & Farron Cousins discuss more.

Drug makers must face claims by purchasers that they conspired to suppress generic competition through an illegal patent settlement.

If you’re a drug manufacturer looking for patients, one company has become a major destination in the past few years: Facebook.

The QALY is a measure that attempts to capture the impact of disease — and the possible beneficial effects of treatment — on both the length and quality of life.

A potential WTO waiver of patent and trade secret protections for Covid-19 vaccines would leave pharmaceutical companies with limited legal avenues to recover costs.

The “it” is a successful, commercial drug launch.

The declines came even as some analysts raised doubts about any near-term pressure on COVID-19 vaccine sales from discussions of waiving intellectual property rights, given the manufacturing complexity and scarcity of raw materials.

If adopted by the World Trade Organisation, the proposal would invite new manufacturers that lack essential know-how and oversight from the inventors to crowd out established contractors.

The proposal was made amid growing concern that low- and middle-income countries were being left out after wealthy nations reached deals with vaccine makers.

In March the FTC filed a lawsuit to block Illumina from reuniting with Grail.

The $92 million figure represents a 6.3% increase over the industry's lobbying spend in the first quarter of last year.

Demand from governments around the world fighting to halt the pandemic could contribute to vaccine sales growth for years to come.

The move came after the government late last year issued a compulsory license to a company called Pharmasyntez, which unsuccessfully approached Gilead about obtaining a license to produce a version of the medicine.